No Data
JMP Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $75
Strategic Advancements and Market Potential Drive Buy Rating for Rhythm Pharmaceuticals
Rhythm Gets FDA Approval for Imcivree for Toddlers
FDA Expands Rhythm Pharma Obesity Drug Approval to Younger Children
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential